LSBCF
Price
$0.77
Change
-$0.01 (-1.28%)
Updated
Oct 17 closing price
Capitalization
31.73M
Intraday Buy/Sell Signals
PROK
Price
$2.97
Change
-$0.07 (-2.30%)
Updated
Oct 17 closing price
Capitalization
400.93M
31 days until earnings call
Intraday Buy/Sell Signals
Interact to see
Advertisement

LSBCF vs PROK

Header iconLSBCF vs PROK Comparison
Open Charts LSBCF vs PROKBanner chart's image
LakeShore Biopharma
Price$0.77
Change-$0.01 (-1.28%)
Volume$4.22K
Capitalization31.73M
ProKidney
Price$2.97
Change-$0.07 (-2.30%)
Volume$790.08K
Capitalization400.93M
LSBCF vs PROK Comparison Chart in %
LSBCF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PROK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
LSBCF vs. PROK commentary
Oct 18, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is LSBCF is a Hold and PROK is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 18, 2025
Stock price -- (LSBCF: $0.77 vs. PROK: $2.97)
Brand notoriety: LSBCF and PROK are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: LSBCF: 7% vs. PROK: 36%
Market capitalization -- LSBCF: $31.73M vs. PROK: $400.93M
LSBCF [@Biotechnology] is valued at $31.73M. PROK’s [@Biotechnology] market capitalization is $400.93M. The market cap for tickers in the [@Biotechnology] industry ranges from $106.87B to $0. The average market capitalization across the [@Biotechnology] industry is $2.06B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

LSBCF’s FA Score shows that 1 FA rating(s) are green whilePROK’s FA Score has 0 green FA rating(s).

  • LSBCF’s FA Score: 1 green, 4 red.
  • PROK’s FA Score: 0 green, 5 red.
According to our system of comparison, both LSBCF and PROK are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

LSBCF’s TA Score shows that 7 TA indicator(s) are bullish while PROK’s TA Score has 6 bullish TA indicator(s).

  • LSBCF’s TA Score: 7 bullish, 3 bearish.
  • PROK’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, LSBCF is a better buy in the short-term than PROK.

Price Growth

LSBCF (@Biotechnology) experienced а -0.01% price change this week, while PROK (@Biotechnology) price change was -1.66% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.56%. For the same industry, the average monthly price growth was +15.88%, and the average quarterly price growth was +79.09%.

Reported Earning Dates

PROK is expected to report earnings on Nov 18, 2025.

Industries' Descriptions

@Biotechnology (+1.56% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
PROK($401M) has a higher market cap than LSBCF($31.7M). PROK YTD gains are higher at: 75.740 vs. LSBCF (-77.746).
LSBCFPROKLSBCF / PROK
Capitalization31.7M401M8%
EBITDAN/A-157.52M-
Gain YTD-77.74675.740-103%
P/E RatioN/AN/A-
RevenueN/A527K-
Total CashN/A295M-
Total DebtN/A4.42M-
TECHNICAL ANALYSIS
Technical Analysis
LSBCFPROK
RSI
ODDS (%)
Bullish Trend 2 days ago
86%
Bearish Trend 2 days ago
83%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
43%
Bearish Trend 2 days ago
72%
Momentum
ODDS (%)
Bullish Trend 2 days ago
63%
Bullish Trend 2 days ago
66%
MACD
ODDS (%)
Bullish Trend 2 days ago
57%
Bullish Trend 2 days ago
76%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
74%
Bearish Trend 2 days ago
69%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
79%
Bullish Trend 2 days ago
71%
Advances
ODDS (%)
Bullish Trend 11 days ago
73%
Bullish Trend 4 days ago
74%
Declines
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
81%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
66%
Bearish Trend 2 days ago
68%
Aroon
ODDS (%)
Bullish Trend 2 days ago
51%
Bullish Trend 2 days ago
73%
View a ticker or compare two or three
Interact to see
Advertisement
LSBCF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PROK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
BCLPX8.56N/A
N/A
BlackRock Event Driven Equity Inv C
PQUAX12.89N/A
N/A
PACE Small/Medium Co Growth Equity A
TFFIX83.86N/A
N/A
Touchstone Focused Instl
NELIX66.18N/A
N/A
Nuveen Equity Long/Short I
WAMCX30.63-0.07
-0.23%
Wasatch Ultra Growth

LSBCF and

Correlation & Price change

A.I.dvisor indicates that over the last year, LSBCF has been loosely correlated with STTK. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if LSBCF jumps, then STTK could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LSBCF
1D Price
Change %
LSBCF100%
-1.29%
STTK - LSBCF
38%
Loosely correlated
+0.56%
BCTX - LSBCF
30%
Poorly correlated
-3.81%
GLTO - LSBCF
27%
Poorly correlated
-12.83%
PROK - LSBCF
26%
Poorly correlated
-2.30%
GNFT - LSBCF
23%
Poorly correlated
+1.92%
More

PROK and

Correlation & Price change

A.I.dvisor indicates that over the last year, PROK has been loosely correlated with RLYB. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if PROK jumps, then RLYB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PROK
1D Price
Change %
PROK100%
-2.30%
RLYB - PROK
45%
Loosely correlated
-3.39%
NRIX - PROK
39%
Loosely correlated
-1.89%
APGE - PROK
38%
Loosely correlated
+3.28%
KYMR - PROK
37%
Loosely correlated
-1.04%
ZYME - PROK
37%
Loosely correlated
-0.81%
More